Boston Scientific Lowers Annual Profit Forecast Due to Slower Watchman Device Adoption
Medical device company Boston Scientific has revised its annual profit forecast downward, citing weaker-than-expected demand for its Watchman heart implant. The decline is attributed to a drop in standalone procedures as doctors increasingly combine the implant with other cardiac treatments during single visits. Despite this challenge, the firm reported strong second-quarter results that beat analyst expectations, with adjusted earnings of 86 cents per share and revenue reaching $5.44 billion. Boston Scientific also announced a restructuring plan aimed at cost-cutting and operational improvements to be completed by late 2029.
Tickers: $BSX